Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1

Cancer

Volumn 109, Issue 7, 2007, Pages 1406-1412

  Ferrari, Andrea ^a   Bisogno, Gianni ^b   Macaluso, Alessandra ^c   Casanova, Michela ^a   D'Angelo, Paolo ^c   Pierani, Paolo ^d   Zanetti, Ilaria ^b   Alaggio, Rita ^b   Cecchetto, Giovanni ^b   Carli, Modesto ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Ospedale dei Bambini G Di Cristina   (Italy)

^d Ospedale Pediatrico G Salesi   (Italy)

Author keywords

Malignant peripheral nerve sheath tumor; Neurofibromatosis; Pediatric soft tissue sarcomas; Rhabdomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HIGH RISK PATIENT; HUMAN; ITALY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NEUROFIBROSARCOMA; PREVALENCE; PRIORITY JOURNAL; REMISSION; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SURVIVAL RATE; TREATMENT RESPONSE; TRITON TUMOR;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS, SECOND PRIMARY; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; NEUROFIBROSARCOMA; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RHABDOMYOSARCOMA; RISK FACTORS; SARCOMA; SURVIVAL RATE;

EID: 33947514688     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22533     Document Type: Article

References (52)

1. Okcu MF, Hicks J, Merchant TE, et al. Nonrhabdomyosarcomatous soft tissue sarcomas. In: Pizzo PA, Poplack DC, eds. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p 1033-1073.
2. Ward BA, Gutmann DH. Neurofibromatosis 1: from lab bench to clinic. Pediatr Neurol. 2005;32:221-228.
3. Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow up of von Recklinghausen neurofibromatosis. N Engl J Med. 1986;314:1010-1015.
4. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51-57.
5. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. 1997;70:138-143.
6. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol. 2002;17:548-554.
7. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181-186.
8. Xu GF, O'Connell P, Viskochil D. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62: 599-608.
9. Wu R, Lopez-Correa C, Rutkowski JL, et al. Germline mutations in NF1 patients with malignancies. Genes Chromosomes Cancer. 1999;26:376-380.
10. Glover TW, Stein CK, Legius E, et al. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer. 1991;3:62-70.
11. Blatt J, Jaffe R, Deutsch M, Adkins JC. Neurofibromatosis and childhood tumors. Cancer. 1986;57:1225-1229.
12. Matsui I, Tanimura M, Kobayashi N, et al. Neurofibromatosis type 1 and childhood cancer. Cancer. 1993;72:2746-2754.
13. Shearer P, Parham D, Kovnar E, et al. Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. Med Pediatr Oncol. 1994;22:78-83.
14. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol. 2005;23: 8422-8430.
15. D'Agostino AN, Soule EH, Miller RH. Sarcomas of the peripheral nerves and somatic soft tissue associated with multiple neurofibromatosis (von Recklinghausen's disease). Cancer. 1963;16:1015-1027.
16. Doorn PF, Molenaar WM, Buter J, et al. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol. 1995;21:78-82.
17. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumours: a clinicopathological study of 120 cases. Cancer. 1986;57:2006-2021.
18. Evans DGR, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-314.
19. Ghosh BC, Ghosh L, Huvos AG, et al. Malignant schwannoma: a clinicalpathological study. Cancer. 1973;31:184-190.
20. Meis JM, Enzinger FM, Martz KL, et al. Malignant peripheral nerve sheath tumors in children. Am J Surg Pathol. 1992;16:694-707.
21. Hartley AL, Birch JM, Mardsen HB. Neurofibromatosis in children with soft tissue sarcomas. Pediatr Hematol Oncol. 1988;5:7-16.
22. Sordillo PP, Kelson L, Hajdu SI, et al. Malignant schwannoma-clinical characteristics, survival, and response to therapy. Cancer. 1981;47:2503-2509.
23. Coffin CM, Cassity J, Viskochil D, et al. Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am J Med Genet A. 2004;127:40-43.
24. Sung L, Anderson JR, Arndt C, et al. Neurofibromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Pediatr. 2004;144: 666-668.
25. Southcott R, Lucraft HH. Association of soft tissue sarcomas other than neurofibrosarcoma with neurofibromatosis. Clin Oncol (R Coll Radiol). 2002;14:431.
26. Casanova M, Ferrari A, Spreafico F, et al. Malignant peripheral nerve sheath tumors in children: a single-institution twenty-year experience. J Pediatr Hematol Oncol. 1999;21: 509-513.
27. Parham DM, Webber BL, Jenkins JJ, et al. Nonrahbdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol. 1995;8: 705-710.
28. Harmer MH. TNM Classification of Pediatric Tumors. Geneva: UICC International Union Against Cancer; 1982. p 23-28.
29. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study I: a final report. Cancer. 1988;61:209-220.
30. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Conover WJ. Practical Nonparametric Statistics. New York: John Wiley & Sons; 1980. p 153-169.
32. Rubin JB, Gutmann DH. Neurofibromatosis type 1-a model for nervous system tumour formation? Nat Rev Cancer. 2005;5:557-564.
33. Upadhyaya M, Shaw DJ, Harper PS. Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and polymorphisms in the NF1 gene. Hum Mutat. 1994;4:83-101.
34. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713-715.
35. Birindelli A, Perrone F, Oggionni M, et al. Pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumours. Lab Invest. 2001;81:833-844.
36. De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003;72:1288-1292.
37. Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 1994;10:250-255.
38. INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath rumours. Clin Cancer Res. 2003;9:4132-4138.
39. Wanebo JE, Malik JM, Van den Berg SR, et al. Malignant peripheral nerve sheath tumours: a clinicopathologic study of 28 cases. Cancer. 1993;71:1247-1253.
40. Hruban RH, Shiu MH, Senie RT, et al. Malignant peripheral nerve sheath tumours of the buttock and lower extremity: a study of 43 cases. Cancer. 1990;66:1253-1265.
41. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumour: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351-360.
42. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065-1074.
43. Glover SJ, Parkin T, Mott M, Quinn AG. Alveolar orbital rhabdomyosarcoma in a patient with neurofibromatosis type 1. Eye. 2001;15:812-813.
44. Hadjistilianou T, Mastrangelo D, Gragnoli A, et al. Letter to the editor: neurofibromatosis type 1 (NF 1) associated with embryonal rhabdomyosarcoma of the orbit. Med Pediatr Oncol. 2002;38:449.
45. Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south-east Wales. II. Guidelines for genetic counselling. J Med Genet. 1989;26: 712-721.
46. McKeen EA, Bodurtha J, Meadows AT, et al. Rhabdomyosarcoma complicating multiple neurofibromatosis. J Pediatr. 1978;93:992-993.
47. Reich S, Overberg-Schmidt US, Leenen A, Henze G. Neurofibromatosis 1 associated with embryonal rhabdomyosarcoma of the urinary bladder. Pediatr Hematol Oncol. 1999; 16:263-266.
48. Ruymann FB, Maddux HR, Ragab A, et al. Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Intergroup Rhabdomyosarcoma Study Committee. Med Pediatr Oncol. 1988; 16:33-39.
49. Warrier RP, Kini KR, Shumaker B, et al. Neurofibromatosis, factor IX deficiency, and rhabdomyosarcoma. Urology. 1986; 28:295-296.
50. Yang P, Grufferman S, Khoury MJ, et al. Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol. 1995;12:467-474.
51. Lampe AK, Seymour G, Thompson PW, et al. Familial neurofibromatosis microdeletion syndrome complicated by rhabdomyosarcoma. Arch Dis Child. 2002;87:444-445.
52. Vogel KS, Klesse IJ, Velasco-Miguel S, et al. Mouse tumour model for neurofibromatosis type 1. Science. 1999;286:2176-2179.